Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/21/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/21/2020.
Displaying: 24 trials in your specialties ()
View trials across your selected specialties

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Carcinoma, Non-Small-Cell Lung
View Full Trial
INTERVENTION

Drug: CC-486, Drug: Pembrolizumab, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Palo Verde Hematology Oncology, Glendale, Arizona, United States

Brief Summary

The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: oral azacitidine, Other: Observation, Drug: First-line chemotherapy after recurrence

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins, Baltimore, Maryland, United States

Brief Summary

To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Acute Myeloid Leukemia, Myelodysplasia
View Full Trial
INTERVENTION

Drug: Oral azacitidine, Drug: Matched placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Heartlands Hospital, Birmingham, United Kingdom

Brief Summary

This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Ep...
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Durvalumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC), and estrogen receptor positive and HER2 negative breast cancer.

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelom...
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: CC-486

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Calvary Mater Newcastle, Newcastle, New South Wales, Australia

Brief Summary

Myelodysplastic Syndrome (MDS) is a group of blood disorders where the bone marrow does not produce enough mature red blood cells, white blood cells and platelets. In a healthy person, the bone marrow makes blood stem cells (immature cells, also called 'blasts') that become mature blood cells over time. In people with MDS, this process is affected and immature blood cells in the bone marrow do not mature fully to become healthy blood cells. This causes a lack of healthy blood cells that can function properly. With fewer healthy blood cells, infection, anaemia, or easy bleeding may occur. MDS can progress to acute myeloid leukaemia in 25-30% of patients, and if untreated it can be rapidly fatal. The purpose of this study is to evaluate the standard treatment, azacitidine (Vidaza) given as an injection under the skin compared to the same medication (called CC-486) taken as a tablet by mouth. Vidaza is approved by the Australian Therapeutics Goods Administration (TGA) as standard treatment for MDS. CC-486 is an experimental treatment. This means it is not an approved treatment for MDS in Australia. CC-486 is being developed to increase convenience and make it easier for patients to continue their treatment. So far it has been given to over 870 patients in studies across the world. The treatment in the injection and the tablet is the same. Studies like this one are being done to ensure the tablet works in the same way as the standard injected treatment. Vidaza is given by subcutaneous injection (ie under the skin) over an hour for 7 days every 4 weeks for as long as it continues to work. All study participants will receive active treatment (there is no placebo), and all participants will receive the standard injection for six treatment cycles followed by the new tablet medication taken once daily for 21 days every 4 weeks. This allows the researchers to compare the two ways of giving the medicine.

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Carcinoma, Non-Small-Cell Lung
View Full Trial
INTERVENTION

Drug: nab-paclitaxel IV, Drug: CC-486, Drug: Duravalumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California San Francisco, San Francisco, California, United States

Brief Summary

This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab, and nab-paclitaxel monotherapy in subjects with advanced non-small cell lung cancer (NSCLC).

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hematologic Neoplasm, Neoplasms
View Full Trial
INTERVENTION

Drug: CC-486

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Florida College of Med, Gainesville, Florida, United States

Brief Summary

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Plasmacytoma, Plasmacytoma of Bone, Multiple Myeloma
View Full Trial
INTERVENTION

Drug: CC-486, Drug: Lenalidomide, Radiation: Radiation Therapy

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

Brief Summary

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Lymphoma, T-Cell
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Romidepsin, Drug: Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National Cancer Center Hospital, Chuo-ku, Japan

Brief Summary

This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene. There will be a combined enrollment target of 86 randomized patients, with approximately 14 randomized patients from Japan. The enrollment to the randomized study will start at European sites in parallel to a safety run-in part in Japan. A safety run-in will be conducted to confirm the tolerability of oral azacitidine at doses of 100 mg and 200 mg QD in Asian patients. Once oral azacitidine at 200 mg QD is confirmed as tolerable, Asian patients from Japan and South Korea will start to be randomized into the main study. Additional patients (non-randomized) are anticipated to enroll to the safety run-in.

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmu...
View Full Trial
INTERVENTION

Drug: Oral azacitidine, Drug: Romidepsin, Drug: Bendamustine, Drug: Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The Christie, Manchester, United Kingdom

Brief Summary

This study evaluates the efficacy of Oral azacitidine versus single-agent Investigator's Choice Therapy in patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.